Mounjaro and the Progesterone-Only Pill: Does Tirzepatide Affect It?

Mounjaro (tirzepatide) slows gastric emptying, which is the main reason prescribers advise women on combined oral contraceptives to add a barrier method during the first four weeks of treatment and after each dose increase.
The progesterone-only pill works primarily by thickening cervical mucus rather than through timed hormone absorption, so the gastric-emptying effect is considered less likely to reduce its reliability.
NHS guidance singles out oral contraceptives specifically — but clinical advice for the POP should still come from your prescriber, because individual circumstances vary.
Tirzepatide carries a Black Triangle (▼) status with the MHRA, meaning it is under additional monitoring; any new or unexpected interactions should be reported via the Yellow Card scheme at yellowcard.mhra.gov.uk.

If you take the progesterone-only pill (POP) and are considering Mounjaro, the short answer is reassuring: current clinical guidance does not flag the same absorption concern for the POP that it does for combined oral contraceptives. That said, the picture is more nuanced than a simple yes or no, and it is worth understanding exactly why the distinction matters before you start treatment. Mounjaro is a prescription-only medicine, and a GPhC-registered prescriber will review your full contraception history as part of any clinical assessment.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The absorption question, the POP, and what prescribers actually advise

The misconception: that Mounjaro's contraception warning covers every oral pill equally

Most people reading about Mounjaro and oral contraception encounter the same headline: add a barrier method when you start, and after each dose increase. That headline is accurate — but it refers specifically to combined oral contraceptives (COCs), the pills that contain both oestrogen and a progestogen. The progesterone-only pill is a different medicine with a different mechanism, and lumping the two together is the most common misreading of this guidance.

Why does the distinction matter? Mounjaro slows the rate at which the stomach empties its contents into the small intestine. For a combined pill, which depends on predictable intestinal absorption to deliver hormones into the bloodstream at the right time, that delay can theoretically reduce the concentration that reaches circulation. That is the mechanism behind the four-week warning. The progesterone-only pill, by contrast, works mainly by making cervical mucus hostile to sperm. It does not rely on the same peak-concentration window, which is why current guidance treats it differently. You can read the NHS's detailed explanation of tirzepatide's interactions on the NHS tirzepatide medicines page.

None of this means the POP is outside the conversation entirely. It means the specific four-week barrier-method rule described in NHS England's wraparound care guidance targets combined pills. The POP still deserves a frank conversation with whoever prescribes your contraception.

What the NHS England guidance actually says, and what it leaves open for the POP

NHS England's guidance on weight-management injections advises that women using oral contraceptives should use a non-oral method for the first four weeks of Mounjaro treatment and for four weeks after every dose increase. The guidance also suggests considering transdermal HRT (patches or gels rather than tablets) for the same absorption reason. The full NHS England page on weight-management injections sets this out clearly for anyone who wants to read the original wording.

Crucially, the explicit four-week rule mentions oral contraceptives as a category. The POP is technically an oral contraceptive, so a cautious prescriber will always want to know you take it. In practice, many clinicians apply common sense: because the POP's effectiveness hinges on different pharmacology, the same urgency does not automatically transfer. But that is a clinical judgement, not a blanket exemption you can apply yourself.

If you take a progestogen-only contraceptive that is not a tablet (an implant, a hormonal coil, or a progestogen-only injection) the absorption question does not arise at all, since those routes bypass the gut entirely.

It is worth spending sixty seconds looking at the patient information leaflet inside your pill packet to confirm which type you take. Combined pills list both an oestrogen (usually ethinylestradiol) and a progestogen; the POP lists only a progestogen. That single check tells you which category you are in before you speak to a prescriber.

Practical steps before starting Mounjaro if you take the POP

Tell your prescriber or GP that you are on the progesterone-only pill before Mounjaro treatment begins. At nume, sorry, at our pharmacy, every consultation is personally reviewed by a GPhC-registered Independent Prescriber who will ask about your contraception as part of a thorough clinical assessment. They are not working from a checkbox; they read your answers and apply clinical judgement to your situation.

You should also loop in whoever issued your POP, whether that is your GP surgery or a sexual health clinic. They can confirm whether anything in your current pill brand or dosing schedule gives them pause alongside a GLP-1 medicine. The conversation is brief, and it removes any ambiguity.

If you are considering switching contraception before starting Mounjaro (for instance, moving to an implant or hormonal coil to sidestep the oral-absorption question altogether) that is a legitimate option some women choose. A prescriber can advise on timing. For broader context on how Mounjaro fits into a weight-management plan, the Mounjaro overview page covers the licensed uses, eligibility criteria, and what to expect from treatment. You can also find a discussion of how the pill more broadly interacts with tirzepatide on the Mounjaro and the pill page, and a parallel look at a related progestogen-only preparation on the norethisterone and Mounjaro page.

The wider picture: hormones, weight loss, and staying safe through treatment

Weight loss itself can affect hormone levels, and that is a background consideration whenever someone on hormonal contraception begins any significant weight-management programme. There is no established evidence that the weight reduction associated with tirzepatide alters progesterone-only pill effectiveness through a hormonal route, but it is another reason your clinical team should have the full picture of what you take.

Mounjaro is a prescription-only medicine licensed for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition such as high blood pressure or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Being on the POP is not, by itself, a barrier to treatment. The tirzepatide page has more detail on the mechanism and the licensed indications if you want to explore further before your consultation, and the Mounjaro and progesterone page looks at progestogens in a broader hormonal context.

Cost is a common question at this stage too. Mounjaro is a private prescription; the Mounjaro pricing page explains what a legitimate private treatment course typically includes, so you know what to expect. When you are ready to take the next step, checking your eligibility through a free consultation with a prescriber is the right starting point.

Ready to talk it through? Check your eligibility with our prescribing team, the consultation is free, and someone real reads every submission the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions